Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology

Written By Yiran Gan
Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology - Lue et al. 2019

Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology

Publication Date: 2019.12.17

Authors: Lih-Fen Lue, Yu-Min Kuo, Marwan Sabbagh

Journal: Neurol Ther (2019) 8 (Suppl 2):S95-S111

Citation

Lih-Fen Lue, Yu-Min Kuo, Marwan Sabbagh, "Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology", Neurol Ther (2019) 8 (Suppl 2):S95-S111.

© 2019 Lue, Kuo and Sabbagh

Neurology and Therapy | Volume 8, Supplement 2, Pages S95-S111

Yiran Gan
Previous

Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer’s disease
Next

Combined Assessment of Serum Alpha-Synuclein and Rab35 is a Better Biomarker for Parkinson's Disease